RxDoctor Payments Data

Robert Okerblom, MD

Family Medicine · Santa Maria, CANPI 1942358643

Payments from drug & device makers

$13,493in general payments, 2019–2025

Across 845 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • GSK$845
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$13,30399%
  • Education$1901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,493 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$706,985
Medicare patients
1,249
Services billed
6,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$129,243
EliquisApixaban91$104,161
JardianceEmpagliflozin64$103,726
MounjaroTirzepatide74$89,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$49,454
TrulicityDulaglutide46$44,094
Repatha SureclickEvolocumab71$42,962
XareltoRivaroxaban21$27,491
FarxigaDapagliflozin Propanediol29$27,030
MyrbetriqMirabegron34$24,421
Synjardy XrEmpagliflozin/Metformin Hcl16$24,003
JanuviaSitagliptin Phosphate16$23,951
CreonLipase/Protease/Amylase11$23,601
EntrestoSacubitril/Valsartan17$17,817
Modafinil14$8,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,057$133,654120 claims
Novo NordiskOzempic$1,191$129,243131 claims
Boehringer IngelheimJardiance, Synjardy Xr$745$127,72980 claims
PfizerEliquis, Premarin$1,104$108,472103 claims
GSKTrelegy Ellipta, Anoro Ellipta$845$55,29168 claims
Johnson & JohnsonXarelto$328$27,49121 claims
AstraZenecaFarxiga$680$27,03029 claims
AbbVieCreon, Synthroid$1,743$26,03848 claims
Astellas Pharma US IncMyrbetriq$317$24,42134 claims
MerckJanuvia$228$23,95116 claims
NovartisEntresto$580$17,81717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →